<DOC>
	<DOCNO>NCT00598975</DOCNO>
	<brief_summary>Study 07-PIR-02 Phase 2 study design evaluate safety efficacy NKTR-102 ( PEG-irinotecan ) treatment patient colorectal cancer ( CRC ) . The study comprise two sequential component - Phase 2a Phase 2b . The Phase 2a portion open-label , dose-finding trial multiple solid tumor type refractory standard curative palliative therapy . The primary endpoint Phase 2a establish /recommended Phase 2 Dose ( RPTD ) NKTR-102 measure frequency Dose Limiting Toxicity ( DLT ) . The Phase 2b portion open-label , randomize , two-arm study patient second-line metastatic colorectal cancer study participant randomize ( 1:1 ) receive either NKTR-102 cetuximab irinotecan cetuximab . The primary endpoint Phase 2b portion trial progression-free survival . Secondary endpoint Phase 2a 2b portion include response rate , response duration , overall survival , standard pharmacokinetics , incidence toxicity , include diarrhea neutropenia .</brief_summary>
	<brief_title>A Phase 2a/2b Multicenter , Open-Label Study Evaluate NKTR 102 Combination With Cetuximab Versus Irinotecan Combination With Cetuximab Second Line Colorectal Cancer Patients</brief_title>
	<detailed_description>The Phase 2a portion study complete . The following entry reflect Phase 2a portion study . The Phase 2b portion study enrol . Based emerge data regard correspond low efficacy cetuximab patient KRAS mutation , well revise NKTR-102 clinical development plan , Phase 2b portionof study complete .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Male nonpregnant , nonlactating female patient ECOG performance score &lt; 3 type solid tumor refractory standard therapy adequate bone marrow organ function screening . Patients must use CYP3A4 inducer inhibitor 2 week prior first day study drug treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Phase 2a : Multiple solid tumor type</keyword>
	<keyword>Phase 2b : Second-Line Colorectal Cancer ( CRC )</keyword>
</DOC>